0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Genelink
Its shares trade under the ticker GNLKQ. It has been listed since 9 March 2000. In the fiscal year to 31 December 2012, it reported revenue of $2.1m and a net loss of $3.1m. At that date it held total assets of $1.5m and shareholders' equity of −$2.7m.
GeneLink, Inc. engages in the development of genetics-based assessment products for pharmaceutical applications and DNA storage purpose. The company is headquartered in Orlando, Florida. The company went IPO on 2000-03-09. The firm offers approximately 12-gene DNA assessment. The firm also formulates a line of genetically guided skin care products. The firm's NGx Health Custom Supplements consist of approximately two types of ingredients: Boost ingredients and Base ingredients. The Boost ingredients are formulated for each of the genes where single nucleotide polymorphisms (SNPs) are found on the customer's DNA assessment. The firm offers supplements, including VDR SNP Boost, EPHX SNP Boost, NQ01 SNP Boost, S0D2 SNPBoost, GPX1 SNP Boost, MMP-1 SNP Boost, MTRR SNP Boost, MTHFR SNP Boost, TNF-alpha SNP Boost, PON-1 SNP Boost, CYP11B2 SNP Boost and APOB SNP Boost. The Base ingredients provide nutrients and other nutritional ingredients.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Mar 2000
- Employees
- 15
- Website
- genelink.com ↗
Leadership
Pay as last reported
- Dr. Bernard KastenExecutive Chairman of the Board, President, Chief Executive Officer, since 2013$95,660
- Michael SmithInterim Chief Financial Officer, Chief Operating Officer
- Dr. Robert RicciardiChief Scientific Officer, Secretary, Director, since 1995$26,500
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Genelink Inc has several strengths that contribute to its success: - Strong brand reputation and recognition in the industry - Extensive experience and expertise in genetic research and testing - Robust and diversified product portfolio offering various genetic testing solutions - Advanced technology infrastructure supporting efficient operations and data analysis - Strong relationships and partnerships with healthcare professionals and institutions - Well-established distribution network reaching a wide customer base - Strong financial position and steady revenue growth - Continuous investment in research and development to drive innovation
Weaknesses
- Despite its strengths, Genelink Inc faces certain weaknesses that need to be addressed: - Limited global presence and market penetration compared to some competitors - Relatively high-cost structure affecting affordability for certain customer segments - Dependence on third-party suppliers for certain components and raw materials - Reliance on regulatory approvals and compliance for product development and marketing - Need for increased marketing and promotional efforts to enhance brand awareness
Opportunities
- Genelink Inc can capitalize on the following opportunities to further expand its business: - Growing demand for personalized medicine and genetic testing globally - Increasing adoption of genetic testing in different sectors, including healthcare, wellness, and sports - Expansion into untapped international markets with high growth potential - Potential collaborations with pharmaceutical companies for joint research and development - Development of innovative products targeting specific genetic disorders - Leveraging big data and analytics to extract valuable insights from genetic information
Threats
- Genelink Inc faces certain threats that may impact its business and market position: - Intense competition from established genetic testing companies and emerging startups - Evolving regulatory and legal landscape regarding genetic testing and data privacy - Potential risks associated with data breaches and privacy concerns - Economic downturns or financial instability affecting customer spending on healthcare - Technological advancements leading to the emergence of new competitive solutions - Changing market trends and consumer preferences in the genetic testing industry
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.